See more : Chosun Refractories Co.,Ltd. (000480.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Solid Biosciences Inc. (SLDB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Solid Biosciences Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- 88 Energy Limited (88E.L) Income Statement Analysis – Financial Results
- Aminex PLC (AEX.L) Income Statement Analysis – Financial Results
- SK Growth Opportunities Corporation (SKGRW) Income Statement Analysis – Financial Results
- CIB Marine Bancshares, Inc. (CIBH) Income Statement Analysis – Financial Results
- Strategic Oil & Gas Ltd. (SOGFF) Income Statement Analysis – Financial Results
Solid Biosciences Inc. (SLDB)
About Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 8.09M | 13.62M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 76.56M | 2.41M | 58.74M | 3.92M | 2.82M | 1.57M | 448.00K | 56.00K | 0.00 |
| Gross Profit | -76.56M | 5.69M | -45.12M | -3.92M | -2.82M | -1.57M | -448.00K | -56.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 70.25% | -331.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 76.56M | 78.42M | 58.74M | 64.88M | 94.74M | 57.97M | 39.91M | 20.12M | 4.19M |
| General & Administrative | 27.75M | 28.95M | 27.14M | 21.58M | 24.58M | 17.72M | 14.95M | 5.46M | 2.37M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.75M | 28.95M | 27.14M | 21.58M | 24.58M | 17.72M | 14.95M | 5.46M | 2.37M |
| Other Expenses | 0.00 | -381.00K | 2.00K | 1.94M | 515.00K | 270.00K | 1.46M | 1.43M | -103.00K |
| Operating Expenses | 104.32M | 107.37M | 85.87M | 86.46M | 119.32M | 75.69M | 54.86M | 25.58M | 6.56M |
| Cost & Expenses | 104.32M | 107.37M | 85.87M | 86.46M | 119.32M | 75.69M | 54.86M | 25.58M | 6.56M |
| Interest Income | 7.14M | 2.62M | 64.00K | 115.00K | 1.58M | 619.00K | 219.00K | 369.00K | 3.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.58M | 2.41M | 2.96M | 3.92M | 2.82M | 1.57M | 448.00K | 56.00K | 6.56M |
| EBITDA | -93.43M | -96.87M | -69.29M | -84.37M | -116.49M | -75.69M | -54.41M | -25.52M | 119.00K |
| EBITDA Ratio | 0.00% | -1,333.38% | -508.74% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -104.32M | -106.45M | -72.25M | -88.41M | -119.32M | -75.69M | -54.86M | -25.58M | -6.56M |
| Operating Income Ratio | 0.00% | -1,315.20% | -530.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.30M | 20.47M | 66.00K | -1.83M | 2.10M | 889.00K | 1.68M | 1.80M | -100.00K |
| Income Before Tax | -96.02M | -85.98M | -72.19M | -88.29M | -117.22M | -74.80M | -53.18M | -23.77M | -6.66M |
| Income Before Tax Ratio | 0.00% | -1,062.28% | -530.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -20.47M | -64.00K | 1.83M | -1.58M | 889.00K | -1.28M | -2.60M | -287.00K |
| Net Income | -96.02M | -65.51M | -72.12M | -90.12M | -115.64M | -74.80M | -52.12M | -21.54M | -6.38M |
| Net Income Ratio | 0.00% | -809.36% | -529.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.83 | -7.70 | -10.13 | -26.03 | -43.05 | -33.73 | -24.26 | -16.80 | -4.97 |
| EPS Diluted | -4.83 | -7.70 | -10.13 | -26.03 | -43.05 | -33.73 | -24.26 | -16.80 | -4.97 |
| Weighted Avg Shares Out | 19.88M | 8.51M | 7.12M | 3.46M | 2.69M | 2.22M | 2.15M | 1.28M | 1.28M |
| Weighted Avg Shares Out (Dil) | 19.88M | 8.51M | 7.12M | 3.46M | 2.69M | 2.22M | 2.15M | 1.28M | 1.28M |
SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024
Solid Biosciences (NASDAQ: SLDB ) just reported results for the first quarter of 2024. Solid Biosciences reported earnings per share of -64 cents.
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 —
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 38,508 restricted stock units (“RSUs”) to two newly hired...
Buy Solid Biosciences: Unpacking Its Main Value Driver
Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving...
How this insider trader nailed every single stock trade
Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on the stock market.
How this insider trader nailed every single stock trade
Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on the stock market.
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to two newly hired employees. These grants were...
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences...
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.
Source: https://incomestatements.info
Category: Stock Reports